참고문헌 (19)

1. 1 Okazaki T , Iwatani S , Yanai T et al. Treatment of lymphangioma in children: our experience of 128 cases . J Pediatr Surg 2007 ; 42 : 386 – 389 . 17270554 

   상세보기

2. 2 Baskota DK , Singh BB , Sinha BK . OK‐432: an effective sclerosing agent for the treatment of lymphangiomas of head and neck . Kathmandu Univ Med J 2007 ; 5 : 312 – 317 . 

3. 3 Ogita S , Tsuto T , Tokiwa K et al. Intracystic injection of OK‐432: a new sclerosing therapy for cystic hygroma in children . Br J Surg 1987 ; 74 : 690 – 691 . 3651773 

   상세보기

4. 4 Rebuffini E , Zuccarino L , Grecchi E et al. Picibanil (OK‐432) in the treatment of head and neck lymphangiomas in children . Dent Res J (Isfahan) 2012 ; 9 : 192 – 196 . 22623937 

5. 5 Rozman Z , Thambidorai RR , Zaleha AM et al. Lymphangioma: is intralesional bleomycin sclerotherapy effective? Biomed Imaging Interv J 2011 ; 7 : e18 . 22279495 

6. 6 Lackner H , Karastaneva A , Schwinger W et al. Sirolimus for the treatment of children with various complicated vascular anomalies . Eur J Pediatr 2015 ; 174 : 1579 – 1584 . 26040705 

   상세보기

7. 7 Danial C , Tichy AL , Tariq U et al. An open‐label study to evaluate sildenafil for the treatment of lymphatic malformations . J Am Acad Dermatol 2014 ; 70 : 1050 – 1057 . 24656411 

   상세보기

8. 8 Ohnishi N , Nagasawa K , Yokoyama T . The verification of regulatory effects of Kampo formulations on body fluid using model mice [in Japanese] . J Med Pharm Soc WAKAN‐YAKU 2000 ; 17 : 131 – 136 . 

9. 9 Ogawa‐Ochiai K , Sekiya N , Kasahara Y et al. A case of mediastinal lymphangioma successfully treated with Kampo medicine . J Altern Complement Med 2011 ; 17 : 563 – 565 . 21568721 

   상세보기

10. 10 Lai CH , Hanson SG , Mallory SB . Lymphangioma circumscriptum treated with pulsed dye laser . Pediatr Dermatol 2001 ; 18 : 509 – 510 . 11841640 

11. 11 Souza RJ , Tone LG . Treatment of lymphangioma with alpha‐2a‐interferon . J Pediatr (Rio J) 2001 ; 77 : 139 – 142 . 14647605 

12. 12 Kasahara Y , Hikino H , Tsurufuji S et al. Antiinflammatory actions of ephedrines in acute inflammations . Planta Med 1985 ; 51 : 325 – 331 . 17340525 

13. 13 Konno C , Mizuno T , Hikino H . Isolation and hypoglycemic activity of ephedrans A, B, C, D and E, glycans of ephedra distachya herbs . Planta Med 1985 ; 2 : 162 – 163 . 4034736 

14. 14 Shiroishi H , Terasawa K , Fuse S et al. Inhibitor effects on fibroblast proliferation of Eppi‐ka‐jyutu‐to, ephedra herba and constitution of ephedra [in Japanese]. J Med Pharm Soc WAKAN‐YAKU 1991 ; 8 : 153 – 161 . 

15. 15 Sidle DM , Maddalozzo J , Meier JD et al. Altered pigment epithelium‐derived factor and vascular endothelial growth factor levels in lymphangioma pathogenesis and clinical recurrence . Arch Otolaryngol Head Neck Surg 2005 ; 131 : 990 – 995 . 16301371 

    상세보기

16. 16 Yeom MJ , Lee HC , Kim GH et al. Anti‐arthritic effects of Ephedra sinica STAPF herb‐acupuncture: inhibition of lipopolysaccharide‐induced inflammation and adjuvant‐induced polyarthritis . J Pharmacol Sci 2006 ; 100 : 41 – 50 . 16404132 

17. 17 Aoki K , Yamakuni T , Yoshida M et al. Ephedorae herba decreases lipopolysaccharide‐induced cyclooxgenase‐2 protein expression and NF‐kappaB‐dependent transcription in C6 rat glioma cells . J Pharmacol Sci 2005 ; 98 : 327 – 330 . 16006736 

18. 18 Luks VL , Kamitaki N , Vivero MP et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somaticmutations in PIK3CA . J Pediatr 2015 ; 166 : 1048 – 1054 . 25681199 

19. 19 Haller CA , Benowitz NL . Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids . N Engl J Med 2000 ; 343 : 1833 – 1838 . 11117974 

    상세보기